Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. (Q47951363)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Tobias Kollmann

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Kinga Smolen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Laura Gelinas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Edgardo S Fortuno

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

7

Mel Krajden

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

5

Meena Dawar

1 reference

27 January 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

author name string

Lisa Franzen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Simon Dobson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

language of work or name

English

0 references

publication date

31 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

3572-3579

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

Human papillomavirus and cervical cancer

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Long-term efficacy of human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Clinician's guide to human papillomavirus immunology: knowns and unknowns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Correlating immunity with protection for HPV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Immune responses to human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Correlates of protection induced by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Identification of B cells through negative gating-An example of the MIFlowCyt standard applied

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Programming the magnitude and persistence of antibody responses with innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

7 January 2021

On immunological memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

A decade of vaccines: Integrating immunology and vaccinology for rational vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Maintenance of serological memory by polyclonal activation of human memory B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Measuring serum antibody to human papillomavirus following infection or vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Cell-mediated immune response to human papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Immunological events in regressing genital warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

The magnitude of CD4+ T cell recall responses is controlled by the duration of the secondary stimulus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

Limited benefit of HPV vaccination for sexually active women in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.051

10.1016/J.VACCINE.2012.03.051

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22469863%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference